Madrigal Pharmaceuticals, Inc. Overview
Pro stress-test →Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Rezdiffra (resmetirom) is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis.
Strategic Profile
Pro stress-test →Madrigal has achieved rapid Rezdiffra revenue growth, now annualizing above $1 billion with a strong first-mover advantage in MASH. The pipeline now exceeds 10 programs anchored by Rezdiffra, with recent licensing deals for complementary mechanisms including ervogastat, a Phase 2 oral DGAT-2 inhibitor and MGL-2086, an oral GLP-1 receptor agonist entering first-in-human studies in Q2 2026.
Competitive Landscape
Pro stress-test →MDGL faces intensifying competition from GLP-1 drugs and emerging FGF21 inhibitors targeting the same MASH market. As the first and only approved MASH treatment, Madrigal holds significant first-mover advantage, but the large market size has attracted major pharma players developing alternative mechanisms.
Industry Context
Madrigal Pharmaceuticals, Inc. operates in Biopharmaceuticals - Hepatology/Metabolic Disease.
Key facts
Headquarters: Conshohocken, PA · Revenue: $1B+